Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ VaccineBiological: PfSPZ Challenge (for CHMI)Other: Normal SalineBiological: PfSPZ Challenge (for PfSPZ-CVac)
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02859350
- Locations
- 🇬🇶
La Paz Medical Center, Malabo, Equatorial Guinea
Sequential Optimization of Dose and Schedule of PfSPZ Vaccine
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ VaccineBiological: PfSPZ Challenge (NF54)Biological: PfSPZ Challenge (7G8)Other: Normal saline
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02704533
- Locations
- 🇩🇪
Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27, Tübingen, Germany
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ VaccineOther: Normal Saline
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 337
- Registration Number
- NCT02687373
- Locations
- 🇰🇪
Center for Global Health Research, KEMRI, Kisian, Siaya County, Kenya
Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Other: Normal SalineBiological: PfSPZ VaccineBiological: PfSPZ Challenge (for CHMI)
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02613520
- Locations
- 🇹🇿
Bagamoyo Research and Training center of the Ifakara Health Institute, Bagamoyo, Tanzania
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
Phase 2
Completed
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ VaccineBiological: CHMI (7G8)Biological: CHMI (NF135.C10)
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT02601716
- Locations
- 🇺🇸
University of Maryland-Baltimore, Center for Vaccine Development, Baltimore, Maryland, United States
🇺🇸Naval Medical Research Center, Silver Spring, Maryland, United States
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
Phase 1
Completed
- Conditions
- MalariaPlasmodium Falciparum
- Interventions
- Biological: PfSPZ VaccineOther: Normal Saline
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02418962
- Locations
- 🇬🇶
La Paz Medical Center, Malabo, Equatorial Guinea
Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
Phase 1
Completed
- Conditions
- Plasmodium Falciparum MalariaMalaria
- Interventions
- Biological: PfSPZ Challenge
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02237586
- Locations
- 🇬🇦
Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses
Phase 1
Completed
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ Vaccine
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02215707
- Locations
- 🇺🇸
Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center, Silver Spring, Maryland, United States
Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults
Phase 1
Completed
- Conditions
- MalariaPlasmodium Falciparum Malaria
- Interventions
- Biological: PfSPZ VaccineBiological: Normal Saline (Placebo)Biological: PfSPZ Challenge
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02132299
- Locations
- 🇹🇿
Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74, Bagamoyo, Tanzania
Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis
Phase 1
Completed
- Conditions
- MalariaPlasmodium Falciparum Malaria
- Interventions
- Biological: PfSPZ ChallengeBiological: 0.9% Sodium Chloride (Placebo)
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Sanaria Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT02115516
- Locations
- 🇩🇪
Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27, Tübingen, Germany
© Copyright 2025. All Rights Reserved by MedPath